SKYE
Skye Bioscience, Inc.
Biotechnology
Market Cap$32M
5Y Perf.-96.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SKYE vs MNMD
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.+217.3%
SKYE vs MNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SKYE | MNMD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $32M | $2.04B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-56M | $-238M |
| Total Debt | $274K | $0.00 |
| Cash & Equiv. | $6M | $258M |
SKYE vs MNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SKYE
MNMD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Skye Bioscience, In… (SKYE) | 100 | 3.6 | -96.4% |
| Mind Medicine (Mind… (MNMD) | 100 | 317.3 | +217.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SKYE vs MNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNMD leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Skye Bioscience, Inc. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
SKYE
Skye Bioscience, Inc.
The Growth Play
SKYE is the clearest fit if your priority is growth exposure.
- EPS growth -93.2%
- 6.7% margin vs MNMD's 1.2%
Best for: growth exposure
MNMD
Mind Medicine (MindMed) Inc.
The Income Pick
MNMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.68
- 5.1% 10Y total return vs SKYE's -99.4%
- Lower volatility, beta 1.68, current ratio 6.29x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNMD | -96.9% revenue growth vs SKYE's -112.9% |
| Quality / Margins | SKYE | 6.7% margin vs MNMD's 1.2% |
| Stability / Safety | MNMD | Beta 1.68 vs SKYE's 2.36 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MNMD | +214.0% vs SKYE's -50.6% |
| Efficiency (ROA) | MNMD | -70.7% ROA vs SKYE's -119.9%, ROIC -389.5% vs -6.0% |
SKYE vs MNMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNMDLAGGINGSKYE
SKYESkye Bioscience, Inc.
1leads
MNMDMind Medicine (MindMe…
3leads
6 Total Categories
CATEGORYLEADERvs SKYEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SKYE1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNMD7/7
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
MNMD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SKYE leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SKYE and MNMD operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | SKYESkye Bioscience, … | MNMDMind Medicine (Mi… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$58M | -$191M |
| Net IncomeAfter-tax profit | -$56M | -$238M |
| Free Cash FlowCash after capex | -$9.2B | -$174M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -50.0% | -163.0% |
SKYE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SKYE and MNMD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SKYESkye Bioscience, … | MNMDMind Medicine (Mi… |
|---|---|---|
| Market CapShares × price | $32M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $26M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.64x | -10.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.78x | 5.56x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SKYE and MNMD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MNMD leads this category, winning 7 of 7 comparable metrics.
Profitability & Efficiency
MNMD delivers a -102.5% return on equity — every $100 of shareholder capital generates $-102 in annual profit, vs $-144 for SKYE. On the Piotroski fundamental quality scale (0–9), MNMD scores 3/9 vs SKYE's 1/9, reflecting mixed financial health.
| Metric | SKYESkye Bioscience, … | MNMDMind Medicine (Mi… |
|---|---|---|
| ROE (TTM)Return on equity | -143.6% | -102.5% |
| ROA (TTM)Return on assets | -119.9% | -70.7% |
| ROICReturn on invested capital | -6.0% | -3.9% |
| ROCEReturn on capital employed | -131.4% | -52.2% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 0.01x | — |
| Net DebtTotal debt minus cash | -$6M | -$258M |
| Cash & Equiv.Liquid assets | $6M | $258M |
| Total DebtShort + long-term debt | $273,646 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | -21.81x |
MNMD leads this category, winning 7 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNMD five years ago would be worth $4,205 today (with dividends reinvested), compared to $399 for SKYE. Over the past 12 months, MNMD leads with a +214.0% total return vs SKYE's -50.6%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs SKYE's -37.9% — a key indicator of consistent wealth creation.
| Metric | SKYESkye Bioscience, … | MNMDMind Medicine (Mi… |
|---|---|---|
| YTD ReturnYear-to-date | +2.3% | +51.7% |
| 1-Year ReturnPast 12 months | -50.6% | +214.0% |
| 3-Year ReturnCumulative with dividends | -76.0% | +510.3% |
| 5-Year ReturnCumulative with dividends | -96.0% | -57.9% |
| 10-Year ReturnCumulative with dividends | -99.4% | +512.1% |
| CAGR (3Y)Annualised 3-year return | -37.9% | +82.7% |
MNMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
MNMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MNMD is the less volatile stock with a 1.68 beta — it tends to amplify market swings less than SKYE's 2.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs SKYE's 15.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SKYESkye Bioscience, … | MNMDMind Medicine (Mi… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.36x | 1.68x |
| 52-Week HighHighest price in past year | $5.75 | $21.09 |
| 52-Week LowLowest price in past year | $0.57 | $6.03 |
| % of 52W HighCurrent price vs 52-week peak | +15.6% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 52.7 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 568K | 792K |
MNMD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SKYESkye Bioscience, … | MNMDMind Medicine (Mi… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $20.00 |
| # AnalystsCovering analysts | — | 1 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNMD leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). SKYE leads in 1 (Income & Cash Flow). 1 tied.
Best OverallMind Medicine (MindMed) Inc. (MNMD)Leads 3 of 6 categories
Loading custom metrics...
SKYE vs MNMD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SKYE or MNMD a better buy right now?
Analysts rate Mind Medicine (MindMed) Inc.
(MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SKYE or MNMD?
Over the past 5 years, Mind Medicine (MindMed) Inc.
(MNMD) delivered a total return of -57. 9%, compared to -96. 0% for Skye Bioscience, Inc. (SKYE). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus SKYE's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SKYE or MNMD?
By beta (market sensitivity over 5 years), Mind Medicine (MindMed) Inc.
(MNMD) is the lower-risk stock at 1. 68β versus Skye Bioscience, Inc. 's 2. 36β — meaning SKYE is approximately 40% more volatile than MNMD relative to the S&P 500.
04Which is growing faster — SKYE or MNMD?
On earnings-per-share growth, the picture is similar: Skye Bioscience, Inc.
grew EPS -93. 2% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SKYE or MNMD?
Skye Bioscience, Inc.
(SKYE) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Mind Medicine (MindMed) Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SKYE leads at 0. 0% versus 0. 0% for MNMD. At the gross margin level — before operating expenses — SKYE leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SKYE or MNMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SKYE or MNMD better for a retirement portfolio?
For long-horizon retirement investors, Mind Medicine (MindMed) Inc.
(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). Skye Bioscience, Inc. (SKYE) carries a higher beta of 2. 36 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNMD: +512. 1%, SKYE: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SKYE and MNMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.